A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys

被引:105
作者
Kumar, S.
Dare, L.
Vasko-Moser, J. A.
James, I. E.
Blake, S. M.
Rickard, D. J.
Hwang, S. -M.
Tomaszek, T.
Yamashita, D. S.
Marquis, R. W.
Oh, H.
Jeong, J. U.
Veber, D. F.
Gowen, M.
Lark, M. W.
Stroup, G.
机构
[1] GlaxoSmithKline Inc, Dept Musculoskeletal Dis, Collegeville, PA 19426 USA
[2] GlaxoSmithKline Inc, Screening & Compound Profiling, Collegeville, PA 19426 USA
[3] GlaxoSmithKline Inc, Med Chem, Collegeville, PA 19426 USA
关键词
cathepsin K; inhibitor; relacatib; bone resorption; monkey; biomarker;
D O I
10.1016/j.bone.2006.07.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cathepsin K is an osteoclast-derived cysteine protease that has been implicated as playing a major role in bone resorption. A substantial body of evidence indicates that cathepsin K is critical in osteoclast-mediated bone resorption and suggests that its pharmacological inhibition should result in inhibition of bone resorption ill vivo. Here we report the pharmacological characterization of SB-462795 (relacatib) as a potent and orally bioavailable small molecule inhibitor of cathepsin K that inhibits bone resorption both ill vitro in human tissue and ill vivo in cynomolgus monkeys. SB-462795 is a potent inhibitor of human cathepsins K, L, and V (K-i,K- app = 41, 68, and 53 pM, respectively) that exhibits 39-300-fold selectivity over other cathepsins. SB-462795 inhibited endogenous cathepsin K ill situ in human osteoclasts and human osteoclast-mediated bone resorption with IC50 values of similar to 45 nM and similar to 70 nM, respectively. The anti-resorptive potential of SB-462795 was evaluated in normal as well as medically ovariectomized (Ovx) female cynomolgus monkeys. Serum levels of the G and N-terminal telopeptides of Type I collagen (CTx and NTx, respectively) and urinary levels of NTx were monitored as biomarkers of bone resorption. Administration of SB-462795 to medically ovariectomized or normal monkeys resulted in an acute reduction in both serum and urinary markers of bone resorption within 1.5 h after dosing, and this effect lasted up to 48 It depending on the dose administered. Our data indicate that SB-462795 potently inhibits human cathepsin K in osteoclasts, resulting in a rapid inhibition of bone resorption both ill vitro and ill vivo in the monkey. These studies also demonstrate the therapeutic potential of relacatib in the treatment of postmenopausal osteoporosis and serves to model the planned clinical trials in human subjects. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:122 / 131
页数:10
相关论文
共 53 条
[1]   Proteolysis of human bone collagen by cathepsin K: Characterization of the cleavage sites generating the cross-linked N-telopeptide neoepitope [J].
Atley, LM ;
Mort, JS ;
Lalumiere, M ;
Eyre, DR .
BONE, 2000, 26 (03) :241-247
[2]   The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis [J].
Black, DM ;
Greenspan, SL ;
Ensrud, KE ;
Palermo, L ;
McGowan, JA ;
Lang, TF ;
Garnero, P ;
Bouxsein, ML ;
Bilezikian, JP ;
Rosen, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (13) :1207-1215
[3]   Proteolytic activity of human osteoclast cathepsin K - Expression, purification, activation, and substrate identification [J].
Bossard, MJ ;
Tomaszek, TA ;
Thompson, SK ;
Amegadzie, BY ;
Hanning, CR ;
Jones, C ;
Kurdyla, JT ;
McNulty, DE ;
Drake, FH ;
Gowen, M ;
Levy, MA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (21) :12517-12524
[4]   Molecular basis and clinical application of biological markers of bone turnover [J].
Calvo, MS ;
Eyre, DR ;
Gundberg, CM .
ENDOCRINE REVIEWS, 1996, 17 (04) :333-368
[5]   Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture [J].
Chesnut, CH ;
Rosen, CJ .
JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (12) :2163-2172
[6]  
Deaton DN, 2004, PROGR MED CHEM, V42, P245, DOI 10.1016/S0079-6468(04)42006-2
[7]   INHIBITION OF BONE-RESORPTION IN CULTURE BY INHIBITORS OF THIOL PROTEINASES [J].
DELAISSE, JM ;
EECKHOUT, Y ;
VAES, G .
BIOCHEMICAL JOURNAL, 1980, 192 (01) :365-368
[8]   Cathepsin K mRNA detection is restricted to osteoclasts during fetal mouse development [J].
Dodds, RA ;
Connor, JR ;
Drake, F ;
Feild, J ;
Gowen, M .
JOURNAL OF BONE AND MINERAL RESEARCH, 1998, 13 (04) :673-682
[9]   Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption [J].
Dodds, RA ;
James, IE ;
Rieman, D ;
Ahern, R ;
Hwang, SM ;
Connor, JR ;
Thompson, SD ;
Veber, DF ;
Drake, FH ;
Holmes, S ;
Lark, MW ;
Gowen, M .
JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (03) :478-486
[10]   Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts [J].
Drake, FH ;
Dodds, RA ;
James, IE ;
Connor, JR ;
Debouck, C ;
Richardson, S ;
LeeRykaczewski, E ;
Coleman, L ;
Rieman, D ;
Barthlow, R ;
Hastings, G ;
Gowen, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (21) :12511-12516